FOLH1 and prostate cancer: A recent pilot study on 14 prostate cancer patients showed that patients with a PSA response ≥ 50% after treatment with 177Lu PSMA had a significantly higher baseline SUVmax in a pre-therapeutic scan with 68Ga PSMA-PET (44 vs. 17) [10].